MedDataX Logo

Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)

NCT ID: NCT00150202

Last Updated: 2007-05-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-07-31

Study Completion Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and Japanese patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

pegaptanib sodium

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Wet AMD, Visual Acuity from 20/320 to 20/40

Exclusion Criteria

* Diabetic retinopathy, laser coagulation history
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Nagoya, Aichi-ken, Japan

Site Status

Pfizer Investigational Site

Urayasu-shi, Chiba, Japan

Site Status

Pfizer Investigational Site

Tokyo, Chiyoda-ku, Japan

Site Status

Pfizer Investigational Site

Fukuoka, Fukuoka, Japan

Site Status

Pfizer Investigational Site

Fukushima, Fukushima, Japan

Site Status

Pfizer Investigational Site

Maebashi, Gunma, Japan

Site Status

Pfizer Investigational Site

Sapporo, Hokkaido, Japan

Site Status

Pfizer Investigational Site

Kida-gun, Kagawa-ken, Japan

Site Status

Pfizer Investigational Site

Kyoto, Kyoto, Japan

Site Status

Pfizer Investigational Site

Moriguchi, Osaka, Japan

Site Status

Pfizer Investigational Site

Suita, Osaka, Japan

Site Status

Pfizer Investigational Site

Ōtsu, Shiga, Japan

Site Status

Pfizer Investigational Site

Mitaka, Tokyo, Japan

Site Status

Pfizer Investigational Site

Shinjuku-ku, Tokyo, Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A5751010

Identifier Type: -

Identifier Source: org_study_id